Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

A Long-Term Assessment of Safety and Physical Function With AMG 108 Subcutaneous Monthly Treatment in Subjects With Rheumatoid Arthritis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00369473

Enrollment

690

Registered

2006-08-29

Start date

2006-09-30

Completion date

2008-06-30

Last updated

2016-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

rheumatoid arthritis

Brief summary

The purpose of this study is to assess long-term safety of SC AMG 108 in the treatment of RA

Interventions

DRUGAMG 108

125 mg via SC (subcutaneous) injection every 4 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll.

Exclusion criteria

* Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.

Design outcomes

Primary

Measure	Time frame
To assess long-term safety of AMG 108 SC in subjects with RA previously enrolled in study 20050168	144 Weeks

Secondary

Measure	Time frame
To determine whether long-term use of AMG 108 improves function in subjects with RA	144 Weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026